HRP20171250T1 - Optimiziranje topivosti imunoveznih sredstava - Google Patents
Optimiziranje topivosti imunoveznih sredstava Download PDFInfo
- Publication number
- HRP20171250T1 HRP20171250T1 HRP20171250TT HRP20171250T HRP20171250T1 HR P20171250 T1 HRP20171250 T1 HR P20171250T1 HR P20171250T T HRP20171250T T HR P20171250TT HR P20171250 T HRP20171250 T HR P20171250T HR P20171250 T1 HRP20171250 T1 HR P20171250T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- acid position
- heavy chain
- chain
- mutation
- Prior art date
Links
- 238000005457 optimization Methods 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 claims 43
- 150000001413 amino acids Chemical group 0.000 claims 43
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 10
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 6
- 239000004473 Threonine Substances 0.000 claims 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000057041 human TNF Human genes 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 231100000989 no adverse effect Toxicity 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Claims (14)
1. Imunovezno sredstvo, naznačeno time, da obuhvaća sljedeće motive pojačanja topivosti na aminokiselinskim pozicijama 12, 103 i 144 jakog lanca (AHo-numeriranje):
(a) serin (S) na aminokiselinskoj poziciji 12 jakog lanca;
(b) serin (S) na aminokiselinskoj poziciji 103 jakog lanca; i
(c) treonin (T) na aminokiselinskoj poziciji 144 jakog lanca; ili
(a1) serin (S) na aminokiselinskoj poziciji 12 jakog lanca;
(b1) treonin (T) na aminokiselinskoj poziciji 103 jakog lanca; i
(c1) serin (S) na aminokiselinskoj poziciji 144 jakog lanca; ili
(a2) serin (S) na aminokiselinskoj poziciji 12 jakog lanca;
(b2) treonin (T) na aminokiselinskoj poziciji 103 jakog lanca; i
(c2) treonin (T) na aminokiselinskoj poziciji 144 jakog lanca.
2. Imunovezno sredstvo prema zahtjevu 1, naznačeno time, da nadalje obuhvaća sljedeće:
(a) aspartna kiselina (D) na aminokiselinskoj poziciji 31 slabog lanca;
(b) glutaminska kiselina (E) na aminokiselinskoj poziciji 83 slabog lanca;
(c) arginin (R) na aminokiselinskoj poziciji 43 jakog lanca;
(d) leukin (L) na aminokiselinskoj poziciji 67 jakog lanca; i/ili
(e) alanin (A) na aminokiselinskoj poziciji 78 jakog lanca.
3. Postupak pojačavanja topivosti imunoveznog sredstva, gdje to imunovezno sredstvo obuhvaća varijabilno područje jakog lanca (VH), ili njegov fragment, naznačen time, da postupak obuhvaća sljedeće:
(A) odabiranje najmanje tri aminokiselinske pozicije unutar
VH-područja za mutaciju; i
(B) mutacija najmanje tri aminokiselinske pozicije koje su odabrane za mutaciju,
pri čemu se kod najmanje tri aminokiselinske pozicije radi o aminokiselinskim pozicijama 12, 103 i 144 jakog lanca (prema AHo-konvenciji numeriranja), te mutacija obuhvaća supstituciju aminokiseline na odabranim aminokiselinskim pozicijama protiv hidrofilne aminokiseline.
4. Postupak prema zahtjevu 3, naznačen time, da je hidrofilna aminokiselina sljedeća:
(a) serin (S) na aminokiselinskoj poziciji 12 jakog lanca;
(b) serin (S) ili treonin (T) na aminokiselinskoj poziciji 103 jakog lanca; i/ili
(c) serin (S) ili treonin (T) na aminokiselinskoj poziciji 144 jakog lanca.
5. Postupak prema zahtjevu 3 ili 4, naznačen time, da se kod aminokiseline koja je odabrana za mutaciju na aminokiselinskoj poziciji radi o hidrofobnoj aminokiselini.
6. Postupak prema zahtjevu 5, naznačen time, da hidrofobna aminokiselina je leukin (L) ili valin (V).
7. Postupak prema bilo kojem od zahtjeva 3 do 6, naznačen time, da se za mutaciju aminokiseline:
(a) na aminokiselinskoj poziciji 12 jakog lanca, odabire aminokiselina valin (V);
(b) na aminokiselinskoj poziciji 103 jakog lanca, odabire aminokiselina valin (V); i
(c) na aminokiselinskoj poziciji 144 jakog lanca, odabire aminokiselina leukin (L).
8. Postupak prema bilo kojem od zahtjeva 3 do 7, naznačen time, da nema štetnog utjecaja na toplinsku stabilnost, ponovno savijanje, doprinos ekspresije, agregaciju i/ili na aktivitet vezanja za imunovezno sredstvo prilikom mutacije.
9. Postupak prema bilo kojem od zahtjeva 3 do 8, naznačen time, da mutacija rezultira s povećanjem topivosti od najmanje dva puta.
10. Postupak prema bilo kojem od zahtjeva 3 do 9, naznačen time, da mutacija dodatno obuhvaća korak uvođenja jedne ili više mutacija na aminokiselinskoj poziciji (AHo-konvencija numeriranja) koja je odabrana od sljedećih:
(a) aspartna kiselina (D) na aminokiselinskoj poziciji 31 slabog lanca;
(b) glutaminska kiselina (E) na aminokiselinskoj poziciji 83 slabog lanca;
(c) arginin (R) na aminokiselinskoj poziciji 43 jakog lanca;
(d) leukin (L) na aminokiselinskoj poziciji 67 jakog lanca; i
(e) alanin (A) na aminokiselinskoj poziciji 78 jakog lanca.
11. Imunovezno sredstvo, naznačeno time, da se pripravlja putem postupka prema bilo kojem od zahtjeva 3 do 10.
12. Imunovezno sredstvo prema bilo kojem od zahtjeva 1, 2 ili 11, naznačeno time, da je to scFv-protutijelo, imunoglobulin pune duljine, Fab-fragment, Dab ili nanotijelo.
13. Imunovezno sredstvo prema bilo kojem od zahtjeva 1, 2, 11 ili 12, naznačeno time, da se to imunovezno sredstvo specifično veže na ljudski TNFα ili na ljudski VEGF.
14. Sastav, naznačen time, da obuhvaća imunovezno sredstvo prema bilo kojem od zahtjeva 1, 2, 11, 12 ili 13, te farmaceutski prihvatljiv nosač.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7569208P | 2008-06-25 | 2008-06-25 | |
| PCT/CH2009/000221 WO2009155725A1 (en) | 2008-06-25 | 2009-06-25 | Solubility optimization of immunobinders |
| EP09768694.3A EP2307455B1 (en) | 2008-06-25 | 2009-06-25 | Solubility optimization of immunobinders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171250T1 true HRP20171250T1 (hr) | 2017-10-20 |
Family
ID=41228195
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171250TT HRP20171250T1 (hr) | 2008-06-25 | 2017-08-16 | Optimiziranje topivosti imunoveznih sredstava |
| HRP20211356TT HRP20211356T1 (hr) | 2008-06-25 | 2021-08-25 | Optimizacija topivosti imunoveziva |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211356TT HRP20211356T1 (hr) | 2008-06-25 | 2021-08-25 | Optimizacija topivosti imunoveziva |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9556265B2 (hr) |
| EP (2) | EP3241843B1 (hr) |
| JP (3) | JP5745720B2 (hr) |
| KR (2) | KR101790567B1 (hr) |
| CN (2) | CN102076715B (hr) |
| AU (1) | AU2009264566B2 (hr) |
| BR (1) | BRPI0914666A2 (hr) |
| CA (1) | CA2728829C (hr) |
| CY (2) | CY1119626T1 (hr) |
| DK (2) | DK3241843T3 (hr) |
| ES (2) | ES2884117T3 (hr) |
| HR (2) | HRP20171250T1 (hr) |
| HU (2) | HUE034827T2 (hr) |
| LT (2) | LT3241843T (hr) |
| MX (2) | MX346024B (hr) |
| PL (2) | PL3241843T3 (hr) |
| PT (2) | PT3241843T (hr) |
| RU (3) | RU2514658C2 (hr) |
| SI (2) | SI2307455T1 (hr) |
| WO (1) | WO2009155725A1 (hr) |
| ZA (1) | ZA201008595B (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102007492B1 (ko) | 2008-06-25 | 2019-08-05 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
| HUE039692T2 (hu) | 2008-06-25 | 2019-01-28 | Esbatech Alcon Biomed Res Unit | TNF-et gátló stabil és oldható ellenanyagok |
| DK3241843T3 (da) | 2008-06-25 | 2021-09-06 | Novartis Ag | Opløselighedsoptimering af immunbindere |
| PL3216803T3 (pl) | 2008-06-25 | 2020-10-19 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące vegf |
| US8399625B1 (en) | 2009-06-25 | 2013-03-19 | ESBATech, an Alcon Biomedical Research Unit, LLC | Acceptor framework for CDR grafting |
| AU2014262201B2 (en) * | 2009-12-23 | 2016-09-15 | Novartis Ag | Method for decreasing immunogenicity |
| CA2777527C (en) | 2009-12-23 | 2020-06-23 | Esbatech, An Alcon Biomedical Research Unit Llc | Method for decreasing immunogenicity |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| JP2014505698A (ja) * | 2011-02-02 | 2014-03-06 | グラクソ グループ リミテッド | 新規抗原結合タンパク質 |
| WO2014068132A1 (en) | 2012-11-05 | 2014-05-08 | Delenex Therapeutics Ag | Binding members to il-1 beta |
| EP4001307A1 (en) | 2012-12-17 | 2022-05-25 | Cell Medica Inc. | Antibodies against il-1 beta |
| RU2015139095A (ru) * | 2013-02-15 | 2017-03-21 | ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи | Акцепторный каркасный участок для пересадки cdr |
| RU2015139890A (ru) * | 2013-02-20 | 2017-03-27 | ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи | Акцепторный каркасный участок для пересадки cdr |
| CN107318267B (zh) | 2013-08-12 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 用于治疗补体相关的病症的组合物和方法 |
| KR20160052562A (ko) * | 2013-09-06 | 2016-05-12 | 에프. 호프만-라 로슈 아게 | 항체 안정성의 개선 방법 |
| EA201692109A1 (ru) | 2014-05-01 | 2017-03-31 | Дженентек, Инк. | Варианты антител к фактору d и их применение |
| ES2685917T3 (es) * | 2015-10-21 | 2018-10-15 | Trinseo Europe Gmbh | Dienos funcionalizados con aminosilano para el uso en la funcionalización de polímeros elastoméricos |
| CN108884164B (zh) | 2016-02-25 | 2022-12-27 | 细胞医学瑞士公司 | 用于免疫疗法的经修饰细胞 |
| CN116848136A (zh) | 2021-02-12 | 2023-10-03 | 勃林格殷格翰国际有限公司 | 补体c3抗原结合蛋白 |
| EP4304725A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| AU2022233285A1 (en) | 2021-03-09 | 2023-10-19 | Cdr-Life Ag | Mage-a4 peptide-mhc antigen binding proteins |
| CA3240046A1 (en) | 2021-12-14 | 2023-06-22 | Cdr-Life Ag | Dual mhc-targeting t cell engager |
| US20240091262A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6740734B1 (en) | 1994-01-14 | 2004-05-25 | Biovitrum Ab | Bacterial receptor structures |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| DE69726003T2 (de) * | 1996-07-16 | 2004-08-26 | Andreas Plückthun | Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| CN1689646A (zh) | 1998-08-11 | 2005-11-02 | 拜奥根Idec公司 | 包括施用抗－cd20抗体的b－细胞淋巴瘤联合疗法 |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| SE9901379D0 (sv) | 1999-04-19 | 1999-04-19 | Pharmacia & Upjohn Ab | Receptor structures |
| US6602977B1 (en) | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
| ATE273323T1 (de) | 1999-12-28 | 2004-08-15 | Esbatech Ag | INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN |
| UA77157C2 (en) | 2000-02-25 | 2006-11-15 | Polypeptide anti-egfrviii scfvs with improved cytotoxicity and output, molecule of nucleic acid, that codes the indicated polypeptide, and method of cell destructure with using of this polypeptide | |
| CA2421447C (en) | 2000-09-08 | 2012-05-08 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
| US6905608B2 (en) | 2002-01-22 | 2005-06-14 | Exergy Technologies Corporation | Advanced electrodeionization for fluid recycling |
| AU2003238370B2 (en) | 2002-05-22 | 2010-04-29 | Novartis Ag | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
| KR20180132969A (ko) * | 2003-05-30 | 2018-12-12 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체를 사용한 치료 |
| AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| US8039588B2 (en) | 2004-05-21 | 2011-10-18 | The Uab Research Foundation | Variable lymphocyte receptors |
| CN102924597A (zh) | 2005-06-07 | 2013-02-13 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 抑制TNFα的稳定和可溶的抗体 |
| SI2046382T1 (sl) | 2006-07-10 | 2016-12-30 | ESBATech an Alcon Biomedical Research Unit LLC | Protitelesa scFv, ki prehajajo epitelijske in/ali endotelijske plasti |
| NZ579594A (en) | 2007-03-12 | 2012-03-30 | Esbatech Alcon Biomed Res Unit | Sequence based engineering and optimization of single chain antibodies |
| WO2009000099A2 (en) | 2007-06-25 | 2008-12-31 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| EP2164961B1 (en) | 2007-06-25 | 2015-01-07 | ESBATech, an Alcon Biomedical Research Unit LLC | Sequence based engineering and optimization of single chain antibodies |
| DK3241843T3 (da) | 2008-06-25 | 2021-09-06 | Novartis Ag | Opløselighedsoptimering af immunbindere |
-
2009
- 2009-06-25 DK DK17161990.1T patent/DK3241843T3/da active
- 2009-06-25 HU HUE09768694A patent/HUE034827T2/en unknown
- 2009-06-25 HU HUE17161990A patent/HUE056090T2/hu unknown
- 2009-06-25 DK DK09768694.3T patent/DK2307455T3/en active
- 2009-06-25 US US13/000,460 patent/US9556265B2/en active Active
- 2009-06-25 PL PL17161990T patent/PL3241843T3/pl unknown
- 2009-06-25 RU RU2011102548/10A patent/RU2514658C2/ru active
- 2009-06-25 CN CN200980123815.6A patent/CN102076715B/zh active Active
- 2009-06-25 KR KR1020167017202A patent/KR101790567B1/ko active IP Right Grant
- 2009-06-25 AU AU2009264566A patent/AU2009264566B2/en active Active
- 2009-06-25 JP JP2011515050A patent/JP5745720B2/ja active Active
- 2009-06-25 SI SI200931674A patent/SI2307455T1/sl unknown
- 2009-06-25 EP EP17161990.1A patent/EP3241843B1/en active Active
- 2009-06-25 EP EP09768694.3A patent/EP2307455B1/en not_active Revoked
- 2009-06-25 CA CA2728829A patent/CA2728829C/en active Active
- 2009-06-25 KR KR1020117001959A patent/KR101650165B1/ko active IP Right Grant
- 2009-06-25 ES ES17161990T patent/ES2884117T3/es active Active
- 2009-06-25 PT PT171619901T patent/PT3241843T/pt unknown
- 2009-06-25 CN CN201511018105.0A patent/CN105418763A/zh active Pending
- 2009-06-25 LT LTEP17161990.1T patent/LT3241843T/lt unknown
- 2009-06-25 ES ES09768694.3T patent/ES2629345T3/es active Active
- 2009-06-25 LT LTEP09768694.3T patent/LT2307455T/lt unknown
- 2009-06-25 PT PT97686943T patent/PT2307455T/pt unknown
- 2009-06-25 PL PL09768694T patent/PL2307455T3/pl unknown
- 2009-06-25 WO PCT/CH2009/000221 patent/WO2009155725A1/en active Application Filing
- 2009-06-25 BR BRPI0914666A patent/BRPI0914666A2/pt not_active Application Discontinuation
- 2009-06-25 MX MX2013011865A patent/MX346024B/es unknown
- 2009-06-25 SI SI200932137T patent/SI3241843T1/sl unknown
- 2009-06-25 MX MX2011000074A patent/MX2011000074A/es active IP Right Grant
-
2010
- 2010-11-30 ZA ZA2010/08595A patent/ZA201008595B/en unknown
-
2014
- 2014-02-10 RU RU2014104577A patent/RU2653441C2/ru active
- 2014-03-18 JP JP2014054856A patent/JP2014111667A/ja active Pending
-
2016
- 2016-04-06 JP JP2016076318A patent/JP2016128517A/ja active Pending
- 2016-12-14 US US15/378,649 patent/US10221237B2/en active Active
-
2017
- 2017-06-22 CY CY20171100670T patent/CY1119626T1/el unknown
- 2017-08-16 HR HRP20171250TT patent/HRP20171250T1/hr unknown
-
2018
- 2018-04-05 RU RU2018112257A patent/RU2018112257A/ru not_active Application Discontinuation
-
2019
- 2019-02-05 US US16/267,460 patent/US11046757B2/en active Active
-
2021
- 2021-08-25 HR HRP20211356TT patent/HRP20211356T1/hr unknown
- 2021-09-22 CY CY20211100832T patent/CY1124644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171250T1 (hr) | Optimiziranje topivosti imunoveznih sredstava | |
| NO2020036I1 (no) | Isolert antistoff eller fragment derav omfattende lett kjede og tung kjede CDR-sekvenser ifølge NO344867 krav 1 (SEQ ID NO: 224, 225, 226 og 146, 147, 148), der antistoffet eller fragmentet derav binder human IL-17 reseptor A; spesielt et antistoff omfattende lett kjede og tung kjede variable domenesekvenser ifølge NO344867 krav 2 (SEQ ID NO: 40 and 14); slik som et IgG2 antistoff omfattende lett og tung kjede variable domenesekvenser ifølge NO344867 krav 4 (SEQ ID NO: 40 and 14); og spesielt brodalumab; og dets derivater dekket av NO344867. | |
| HRP20201091T1 (hr) | Protutijela anti-axl | |
| HRP20230761T1 (hr) | Gdf zamke | |
| PE20200717A1 (es) | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas | |
| HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
| WO2013061163A3 (en) | Tdp-43 specific binding molecules | |
| FR2890912B1 (fr) | Siege de vehicule. | |
| FR2925318B1 (fr) | Composition comprenant une alcanolamine, un acide amine et un polymere associatif. | |
| PE20141522A1 (es) | Proteinas y peptidos modificados | |
| CL2013003090A1 (es) | Polipeptido que comprende una primera secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17f, il17-a/f, pero no a il-17a, y una segunda secuencia de aminoacidos que comprende a su vez al menos un dominio variable individual de inmunoglobulina que se enlaza especificamente a il-17a, il-17f y il17-a/f; composicion farmaceutica que lo comprende; y su uso. | |
| NO20082634L (no) | Bindigsproteiner spesifikke for insulin-lignende vekstfaktorer og anvendelser derav | |
| ES2566737T3 (es) | Métodos de modificación de anticuerpos y anticuerpos modificados con propiedades funcionales mejoradas | |
| DE602006008651D1 (de) | Verfahren und verpackung für back-, auftauwaren bzw. mikrowellentaugliche waren | |
| DE602006009652D1 (de) | Eine herstellungsmethode von entacapon-enthaltenden granulaten für orale dosierformen | |
| CY1113346T1 (el) | Καινοφανη ενδιαμεσα προϊοντα χρησιμα στην παρασκευη της ενωσης του αλφα-(ν-σουλφοναμιδο)ακεταμιδιου | |
| BRPI0817294A2 (pt) | Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr. | |
| EA200970255A1 (ru) | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение | |
| CU23719A3 (es) | Anticuerpo e inmunoconjugado con actividad neutralizante del virus de la rabia, molécula de ácido nucleico y vector | |
| WO2009004066A3 (en) | Providing improved immunoglobulin sequences by mutating cdr and/or fr positions | |
| ZA200810473B (en) | 2-arylpyrazolo[L,5-+-]pyrimidin-3-yl acetamide derivatives as ligands for translocation protein (18 kda) | |
| WO2008133641A3 (en) | Antibodies directed to gpnmb and uses thereof | |
| ATE462140T1 (de) | Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate | |
| ATE487142T1 (de) | Proteinnachweisreagentien und -verfahren mit farbstoffen und dextrinen | |
| EA200900729A1 (ru) | Получение твёрдых растворов пестицидов путём кратковременного нагревания и быстрого высушивания |